Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia

Lancet Oncol. 2010 Nov;11(11):1010-1. doi: 10.1016/S1470-2045(10)70243-6. Epub 2010 Oct 19.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Drug Administration Schedule
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / genetics
  • Gene Expression Regulation, Leukemic
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Piperazines / administration & dosage
  • Protein Kinase Inhibitors / administration & dosage*
  • Pyrimidines / administration & dosage
  • Recurrence
  • Remission Induction
  • Survival Rate
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • abl-bcr fusion protein, human
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl